Multiple atherosclerosis-related biomarkers associated with short- and long-term mortality after stroke

Clinical Biochemistry

Volumn 45, Issue 16-17, 2012, Pages 1308-1315

  Chan, Cangel Pui Yee ^a   Jiang, Hui Lin ^b   Leung, Ling Yan ^a   Wan, Wai Man ^c   Cheng, Nga Man ^c   Ip, Wai Sze ^c   Cheung, Kwan Yee ^c   Chan, Rebecca Wing Yan ^a   Wong, Lawrence Ka Sing ^a   Graham, Colin Alexander ^a   Renneberg, Reinhard ^c   Rainer, Timothy Hudson ^a  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^b GUANGZHOU MEDICAL UNIVERSITY   (China)

^c HONG KONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Hong Kong)

Author keywords

High sensitivity C reactive protein (hs CRP); Lipocalin 2 (LCN2); Matrix metalloproteinase 9 (MMP9); Mortality; Myeloperoxidase (MPO); Stroke

Indexed keywords

C REACTIVE PROTEIN; GELATINASE B; MESSENGER RNA; MYELOPEROXIDASE; NEUTROPHIL GELATINASE ASSOCIATED LIPOCALIN;

ADULT; AGED; ARTICLE; ATHEROSCLEROSIS; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PREDICTIVE VALUE; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION;

ACUTE-PHASE PROTEINS; AGED; AGED, 80 AND OVER; ATHEROSCLEROSIS; BIOLOGICAL MARKERS; BRAIN ISCHEMIA; C-REACTIVE PROTEIN; FEMALE; GLASGOW COMA SCALE; HUMANS; INTRACRANIAL HEMORRHAGES; KAPLAN-MEIER ESTIMATE; LIPOCALINS; MALE; MATRIX METALLOPROTEINASE 9; MIDDLE AGED; MULTIVARIATE ANALYSIS; PEROXIDASE; PROTO-ONCOGENE PROTEINS; RNA, MESSENGER; ROC CURVE;

EID: 84868301692     PISSN: 00099120     EISSN: 18732933     Source Type: Journal    
DOI: 10.1016/j.clinbiochem.2012.06.014     Document Type: Article

References (40)

1. Ross R., Bu D.X., Hemdahl A.L., Gabrielsen A., Fuxe J., Zhu C., et al. Atherosclerosis - an inflammatory disease. N Engl J Med 1999, 340(2):115-126.
2. Pearson T.A., Mensah G.A., Alexander R.W., Anderson J.L., Cannon R.O., Criqui M., et al. Markers of inflammation and cardiovascular disease: application to clinical and public health practice: a statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation 2003, 107(3):499-511.
3. Wang Q., Tang X.N., Yenari M.A. The inflammatory response in stroke. J Neuroimmunol 2006, 184:53-68.
4. Calabró P., Willerson J.T., Yeh E.T. Inflammatory cytokines stimulated C-reactive protein production by human coronary artery smooth muscle cells. Circulation 2003, 108(16):1930-1932.
5. Verma S., Wang C.H., Li S.H., Dumont A.S., Fedak P.W., Badiwala M.V., et al. A self-fulfilling prophecy: C-reactive protein attenuates nitric oxide production and inhibits angiogenesis. Circulation 2002, 106(8):913-919.
6. Danenberg H.D., Szalai A.J., Swaminathan R.V., Peng L., Chen Z., Seifert P., et al. Increased thrombosis after arterial injury in human C-reactive protein-transgenic mice. Circulation 2003, 108(5):512-515.
7. Kaptoge S., Di Angelantonio E., Lowe G., Pepys M.B., Thompson S.G., Collins R., et al. C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant meta-analysis. Lancet 2010, 375(9709):132-140.
8. Eldrup N., Grønholdt M.L., Sillesen H., Nordestgaard B.G. Elevated matrix metalloproteinase-9 associated with stroke or cardiovascular death in patients with carotid stenosis. Circulation 2006, 114(17):1847-1854.
9. Gidday J.M., Gasche Y.G., Copin J.C., Shah A.R., Perez R.S., Shapiro S.D., et al. Leukocyte-derived matrix-metalloproteinase-9 mediates blood-brain barrier breakdown and is proinflammatory after transient focal cerebral ischemia. Am J Physiol Heart Circ Physiol 2005, 289:558-568.
10. Abilleira S., Montaner J., Molina C.A., Monasterio J., Castillo J., Alvarez-Sabín J. Matrix metalloproteinase-9 concentration after spontaneous intracerebral hemorrhage. J Neurosurg 2003, 99:65-70.
11. Tang Y., Xu H., Du X., Lit L., Walker W., Lu A., et al. Gene expression in blood changes rapidly in neutrophils and monocytes after ischemic stroke in humans: a microarray study. J Cereb Blood Flow Metab 2006, 26:1089-1102.
12. Graham C.A., Chan R.W., Chan D.Y., Chan C.P., Wong L.K., Rainer T.H. Matrix metalloproteinase 9 mRNA: An early prognostic marker for patients with acute stroke. Clin Biochem 2012, 45:352-355.
13. Yan L., Borregaard N., Kjeldsen L., Moses M.A. The high molecular weight urinary matrix metalloproteinase (MMP) activity is a complex of gelatinase B/MMP-9 and neutrophil gelatinase-associated lipocalin (NGAL). Modulation of MMP-9 activity by NGAL. J Biol Chem 2001, 276:37258-37265.
14. Anwaar I., Gottsäter A., Ohlsson K., Mattiasson I., Lindgärde F. Increasing levels of leukocyte-derived inflammatory mediators in plasma and cAMP in platelets during follow-up after acute cerebral ischemia. Cerebrovasc Dis 1998, 8(6):310-317.
15. Elneihoum A.M., Falke P., Axelsson L., Lundberg E., Lindgärde F., Ohlsson K. Leukocyte activation detected by increased plasma levels of inflammatory mediators in patients with ischemic cerebrovascular diseases. Stroke 1996, 27(10):1734-1738.
16. Falke P., Elneihoum A.M., Ohlsson K. Leukocyte activation: relation to cardiovascular mortality after cerebrovascular ischemia. Cerebrovasc Dis 2000, 10(2):97-101.
17. Hazen S.L. Myeloperoxidase and plaque vulnerability. Arterioscler Thromb Vasc Biol 2004, 24(7):1143-1146.
18. Baldus S., Heeschen C., Meinertz T., Zeiher A.M., Eiserich J.P., Münzel T., et al. Myeloperoxidase serum levels predict risk in patients with acute coronary syndromes. Circulation 2003, 108(12):1440-1445.
19. Lau D., Baldus S. Myeloperoxidase and its contributory role in inflammatory vascular disease. Pharmacol Ther 2006, 111(1):16-26.
20. Domínguez C., Delgado P., Vilches A., Martín-Gallán P., Ribó M., Santamarina E., et al. Oxidative stress after thrombolysis-induced reperfusion in human stroke. Stroke 2010, 41(4):653-660.
21. Cojocaru I.M., Cojocaru M., Iliescu I., Botnaru L., Gurban C.V., Sfrijan F., et al. Plasma myeloperoxidase levels in patients with acute ischemic stroke. Rom J Intern Med 2010, 48(1):101-104.
22. Hoy A., Leininger-Muller B., Poirier O., Siest G., Gautier M., Elbaz A., et al. Myeloperoxidase polymorphisms in brain infarction. Association with infarct size and functional outcome. Atherosclerosis 2003, 167(2):223-230.
23. Manso H., Krug T., Sobral J., Albergaria I., Gaspar G., Ferro J.M., et al. Variants in the inflammatory IL6 and MPO genes modulate stroke susceptibility through main effects and gene-gene interactions. J Cereb Blood Flow Metab 2011, 31(8):1751-1759.
24. Special report from the National Institute of Neurological Disorders and Stroke: classification of cerebrovascular diseases III. Stroke 1990, 21:637-676.
25. Hartmann A., Rundek T., Mast H., Paik M.C., Boden-Albala B., Mohr J.P., et al. Mortality and causes of death after first ischemic stroke: the Northern Manhattan Stroke Study. Neurology 2001, 57(11):2000-2005.
26. Whiting R., Shen Q., Hung W.T., Cordato D., Chan D.K. Predictors for 5-year survival in a prospective cohort of elderly stroke patients. Acta Neurol Scand 2011, 124(5):309-316.
27. Kammersgaard L.P., Olsen T.S. Cardiovascular risk factors and 5-year mortality in the Copenhagen Stroke Study. Cerebrovasc Dis 2006, 21(3):187-193.
28. Putaala J., Curtze S., Hiltunen S., Tolppanen H., Kaste M., Tatlisumak T. Causes of death and predictors of 5-year mortality in young adults after first-ever ischemic stroke: the Helsinki Young Stroke Registry. Stroke 2009, 40(8):2698-2703.
29. Godoy-Torres D.A., Pineiro G. Inflammatory response in spontaneous intracerebral haemorrhage. Rev Neurol 2005, 40:492-497.
30. Kleinig T.J., Vink R. Suppression of inflammation in ischemic and hemorrhagic stroke: therapeutic options. Curr Opin Neurol 2009, 22:294-301.
31. Delgado P., Cuadrado E., Rosell A., Alvarez-Sabín J., Ortega-Aznar A., Hernández-Guillamón M., et al. Fas system activation in perihematomal areas after spontaneous intracerebral hemorrhage. Stroke 2008, 39:1730-1734.
32. Blaschke F., Bruemmer D., Yin F., Takata Y., Wang W., Fishbein M.C., et al. C-reactive protein induces apoptosis in human coronary vascular smooth muscle cells. Circulation 2004, 110:579-587.
33. Idicula T.T., Brogger J., Naess H., Waje-Andreassen U., Thomassen L. Admission C-reactive protein after acute ischemic stroke is associated with stroke severity and mortality: the 'Bergen stroke study'. BMC Neurol 2009, 9:18.
34. Alexandrova M.L., Danovska M.P. Serum C-reactive protein and lipid hydroperoxides in predicting short-term clinical outcome after spontaneous intracerebral hemorrhage. J Clin Neurosci 2011, 18(2):247-252.
35. Castellanos M., Leira R., Serena J., Pumar J.M., Lizasoain I., Castillo J., et al. Plasma metalloproteinase-9 concentration predicts hemorrhagic transformation in acute ischemic stroke. Stroke 2003, 34(1):40-46.
36. Hamann G.F., Okada Y., del Zoppo G.J. Hemorrhagic transformation and microvascular integrity during focal cerebral ischemia/reperfusion. J Cereb Blood Flow Metab 1996, 16(6):1373-1378.
37. Leclercq A., Houard X., Philippe M., Ollivier V., Sebbag U., Meilhac O., et al. Involvement of intraplaque hemorrhage in atherothrombosis evolution via neutrophil protease enrichment. J Leukoc Biol 2007, 82(6):1420-1429.
38. Hemdahl A.L., Gabrielsen A., Zhu C., Eriksson P., Hedin U., Kastrup J., et al. Expression of neutrophil gelatinase-associated lipocalin in atherosclerosis and myocardial infarction. Arterioscler Thromb Vasc Biol 2006, 26(1):136-142.
39. Yndestad A., Landrø L., Ueland T., Dahl C.P., Flo T.H., Vinge L.E., et al. Increased systemic and myocardial expression of neutrophil gelatinase-associated lipocalin in clinical and experimental heart failure. Eur Heart J 2009, 30(10):1229-1236.
40. Elkind M.S., Tai W., Coates K., Paik M.C., Sacco R.L. High-sensitivity C-reactive protein, lipoprotein-associated phospholipase A2, and outcome after ischemic stroke. Arch Intern Med 2006, 166(19):2073-2080.